Vaagn Andikyan, MD
Assistant Professor of Obstetrics, Gynecology and Reproductive Sciences
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer StagingAlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
- Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315)McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- Delayed presentation of placenta accreta following a first‐trimester medical abortionMaurer J, Ramani S, Xu B, Gallousis S, Clark M, Andikyan V. Delayed presentation of placenta accreta following a first‐trimester medical abortion. Clinical Case Reports 2023, 11: e7849. PMID: 37636882, PMCID: PMC10457480, DOI: 10.1002/ccr3.7849.
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerGelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- Effectiveness of telehealth physical therapy for patients with pelvic floor disorders in a community hospital settingCoad B, Ramani S, Michel L, Peled A, Morgan J, Hartnett J, Chudnoff S, Andikyan V. Effectiveness of telehealth physical therapy for patients with pelvic floor disorders in a community hospital setting. Archives Of Gynecology And Obstetrics 2023, 308: 661-665. PMID: 37268794, PMCID: PMC10238233, DOI: 10.1007/s00404-023-07078-6.
- Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Incisional infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for suspected gynecologic malignancy: a pilot studyMoon A, Andikyan V, Agarwal R, Stroever S, Misita D, Laibangyang A, Doo D, Chuang L. Incisional infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for suspected gynecologic malignancy: a pilot study. Gynecologic Oncology Reports 2023, 47: 101203. PMID: 37251783, PMCID: PMC10220396, DOI: 10.1016/j.gore.2023.101203.
- Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancerMcNamara B, Demirkiran C, Bellone S, Mutlu L, Zipponi M, Verzosa M, Harold J, Hartwich T, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Santin A. Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer. Cancer Research 2023, 83: 3402-3402. DOI: 10.1158/1538-7445.am2023-3402.
- Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorMcNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemicSullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.
- The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoHan C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies.Ramani S, Hartnett J, Karki S, Gallousis S, Clark M, Andikyan V. Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2023, 27: e2023.00021. PMID: 37663433, PMCID: PMC10473183, DOI: 10.4293/jsls.2023.00021.
- Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcomaHarold J, Manavella D, Bellone S, Siegel E, Hartwich T, Zammataro L, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma. 2022, a51.1-a51. DOI: 10.1136/ijgc-2022-igcs.98.
- Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047)Mutlu L, Manavella D, Bellone S, Harold J, Mauricio D, Tymon-Rosario J, Siegel E, Hartwich T, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047). Gynecologic Oncology 2022, 166: s32-s33. DOI: 10.1016/s0090-8258(22)01266-5.
- Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043)Tymon-Rosario J, Manara P, Manavella D, Bellone S, Siegel E, Hartwich T, Harold J, Zammataro L, Yang-Hartwich Y, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043). Gynecologic Oncology 2022, 166: s30. DOI: 10.1016/s0090-8258(22)01262-8.
- Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)Manavella D, Harold J, Bellone S, Hartwich T, Mutlu L, Tymon-Rosario J, Siegel E, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011). Gynecologic Oncology 2022, 166: s9. DOI: 10.1016/s0090-8258(22)01229-x.
- Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)Mauricio D, Bellone S, Manavella D, Harold J, Buza N, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046). Gynecologic Oncology 2022, 166: s31-s32. DOI: 10.1016/s0090-8258(22)01265-3.
- BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)Harold J, Manavella D, Bellone S, Siegel E, Mauricio D, Hartwich T, Zammataro L, Mutlu L, AlAshqar A, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212). Gynecologic Oncology 2022, 166: s118. DOI: 10.1016/s0090-8258(22)01437-8.
- Abstract 70: Metastatic versus primary: Genomic analysis suggests a metastatic origin for breast cancer previously diagnosed as metachronous vulvar ectopic breast cancerSwierczek S, Pandya D, Billaud J, Reva B, Swierczek M, Reeves M, Farisello S, Sieber S, Laibangyang A, Andikyan V, Martignetti J, Chuang L. Abstract 70: Metastatic versus primary: Genomic analysis suggests a metastatic origin for breast cancer previously diagnosed as metachronous vulvar ectopic breast cancer. Cancer Research 2022, 82: 70-70. DOI: 10.1158/1538-7445.am2022-70.
- Abstract 1629: Integrated genomic and functional characterization of type I and II endometrial cancers reveals unexpected differences in novel candidate treatmentsPandya D, Swierczek S, Billaud J, Farisello S, Swierczek M, Sieber S, Andikyan V, Chuang L, Martignetti J. Abstract 1629: Integrated genomic and functional characterization of type I and II endometrial cancers reveals unexpected differences in novel candidate treatments. Cancer Research 2022, 82: 1629-1629. DOI: 10.1158/1538-7445.am2022-1629.
- EPV257/#152 Surgical site infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for gynecologic malignancy: a prospective randomized controlled trialMoon A, andikyan V, Agarwal R, Stroever S, Misita D, Laibangyang A, Doo D, Chuang L. EPV257/#152 Surgical site infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for gynecologic malignancy: a prospective randomized controlled trial. International Journal Of Gynecological Cancer 2021, 31: a130-a130. DOI: 10.1136/ijgc-2021-igcs.328.
- Laparoscopic Resection of Parasitic Fibroids after HysterectomyMichel L, Sullivan M, Picon A, Andikyan V. Laparoscopic Resection of Parasitic Fibroids after Hysterectomy. Journal Of Minimally Invasive Gynecology 2021, 28: s120-s121. DOI: 10.1016/j.jmig.2021.09.197.
- Two-Port Robotic Laparoscopic HysterectomyMauricio D, Webster E, Harold J, Altwerger G, Azodi M, Clark M, Huang G, Menderes G, Ratner E, Santin A, Schwartz P, Andikyan V. Two-Port Robotic Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2021, 28: s155. DOI: 10.1016/j.jmig.2021.09.315.
- In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinomaTymon-Rosario J, Bonazzoli E, Guglielmi A, Bellone S, Nagarkatti N, Zammataro L, Zeybek B, Harold J, Mauricio D, Clark M, Andikyan V, Huang G, Altwerger G, Menderes G, Azodi M, Ratner E, Schwartz P, Santin A. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. Gynecologic Oncology 2021, 162: s186-s187. DOI: 10.1016/s0090-8258(21)01001-5.
- Financial toxicity in patients with gynecologic malignanciesZeybek B, Webster E, Pogosian N, Tymon-Rosario J, Mauricio D, Harold J, Menderes G, Altwerger G, Malette J, Luther M, Baker L, Balch A, Clark M, Huang G, Azodi M, Ratner E, Schwartz P, Santin A, Andikyan V. Financial toxicity in patients with gynecologic malignancies. Gynecologic Oncology 2021, 162: s162. DOI: 10.1016/s0090-8258(21)00950-1.
- Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective reviewWebster E, Arkfeld C, Chang Y, Yadav G, Zeybek B, Tymon-Rosario J, Harold J, Clark M, Andikyan V, Huang G, Menderes G, Azodi M, Santin A, Schwartz P, Ratner E, Altwerger G. Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review. Gynecologic Oncology 2021, 162: s108. DOI: 10.1016/s0090-8258(21)00848-9.
- Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
- Opioid Consumption after Transversus Abdominis Plane Block in Abdominal HysterectomyMoon A, Wakefield D, Petrini J, Andikyan V, Panarelli E. Opioid Consumption after Transversus Abdominis Plane Block in Abdominal Hysterectomy. Obstetrics And Gynaecology Cases - Reviews 2020, 7 DOI: 10.23937/2377-9004/1410182.
- Integrated genomic and functional analysis of patient-derived sarcoma cell lines validates their use for candidate treatment discovery including knockdown of a novel BCOR fusion gene.Swierczek S, Pandya D, Billaud J, Vigil Dominguez I, Farisello S, Sieber S, Chen Y, Chuang L, Andikyan V, Martignetti J. Integrated genomic and functional analysis of patient-derived sarcoma cell lines validates their use for candidate treatment discovery including knockdown of a novel BCOR fusion gene. Journal Of Clinical Oncology 2020, 38: e23572-e23572. DOI: 10.1200/jco.2020.38.15_suppl.e23572.
- Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancerPandya D, Tomita S, Camacho O, Swierczek S, Camacho C, Engelman K, Polukort S, Padron M, RoseFigura J, Irish J, Chuang L, Andikyan V, Cohen S, Fiedler P, Sieber S, Shih I, Billaud J, Reva B, Sebra R, Dottino P, Martignetti J. Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer. Cancer Research 2019, 79: 2729-2729. DOI: 10.1158/1538-7445.am2019-2729.
- Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancerPandya D, Tomita S, Camacho O, Swierczek S, Camacho C, Engelman K, Polukort S, Padron M, RoseFigura J, Irish J, Chuang L, Andikyan V, Cohen S, Fiedler P, Sieber S, Shih I, Billaud J, Reva B, Sebra R, Dottino P, Martignetti J. Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer. 2019, 2729-2729. DOI: 10.1158/1538-7445.sabcs18-2729.
- A prospective study assessing quality of life in women after pelvic exenterationFilippova O, Cowan R, Baser R, Suidan R, Andikyan V, Sonoda Y, Zivanovic O, Bochner B, Carter J, Chi D. A prospective study assessing quality of life in women after pelvic exenteration. Gynecologic Oncology 2019, 154: 201. DOI: 10.1016/j.ygyno.2019.04.467.
- Metastatic Gastric Adenocarcinoma Masked as Ectopic Pregnancy [39E]Moon A, Yu J, Henriquez J, Fairbairn M, Chuang L, Andikyan V. Metastatic Gastric Adenocarcinoma Masked as Ectopic Pregnancy [39E]. Obstetrics And Gynecology 2019, 133: 61s-61s. DOI: 10.1097/01.aog.0000559031.74177.ab.
- Sweet Syndrome Following Gynecologic Surgery: Pelvic Abscess as a CauseCornacchia M, Munger D, Andikyan V, Halasz C. Sweet Syndrome Following Gynecologic Surgery: Pelvic Abscess as a Cause. SKIN The Journal Of Cutaneous Medicine 2019, 3 DOI: 10.25251/skin.3.1.8.
- Enhanced Recovery after Surgery (ERAS) in Gynecologic Surgery—A ReviewMoon A, Tangada A, Andikyan V, Chuang L. Enhanced Recovery after Surgery (ERAS) in Gynecologic Surgery—A Review. Current Obstetrics And Gynecology Reports 2018, 7: 122-132. DOI: 10.1007/s13669-018-0247-1.
- Surgical management of ovarian tumors without the support of intraoperative pathology readings in Bhaktapur Cancer HospitalShrestha E, Thapa A, Tuladhar R, Marinone M, Andikyan V, Chuang L. Surgical management of ovarian tumors without the support of intraoperative pathology readings in Bhaktapur Cancer Hospital. Gynecologic Oncology 2018, 149: 241. DOI: 10.1016/j.ygyno.2018.04.545.
- Ovarian neoplasia: Characteristics and diagnostic concordance between ultrasound, tumor markers and histopathology in Honduras 2015-2016Bourdeth A, Moon A, Jerez R, Andikyan V, Chuang L, Alger J. Ovarian neoplasia: Characteristics and diagnostic concordance between ultrasound, tumor markers and histopathology in Honduras 2015-2016. Gynecologic Oncology 2018, 149: 242. DOI: 10.1016/j.ygyno.2018.04.546.
- Laparoscopic Resection of Para-Aortic Tumor Recurrence Using Kocher Maneuver Duodenal MobilizationFalk K, Andikyan V, Kolev V. Laparoscopic Resection of Para-Aortic Tumor Recurrence Using Kocher Maneuver Duodenal Mobilization. Journal Of Minimally Invasive Gynecology 2016, 23: s139. DOI: 10.1016/j.jmig.2016.08.417.
- Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of lifeCowan R, Suidan R, Andikyan V, Rezk Y, Einstein H, Chang K, Zivanovic O, Gardner G, Sonoda Y, Chi D. Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life. Gynecologic Oncology 2016, 141: 175. DOI: 10.1016/j.ygyno.2016.04.455.
- 21: Laparoscopic radical hysterectomy for stage IIA1 cervical cancerMandelberger A, Andikyan V, Kolev V. 21: Laparoscopic radical hysterectomy for stage IIA1 cervical cancer. American Journal Of Obstetrics And Gynecology 2016, 214: s514. DOI: 10.1016/j.ajog.2016.01.134.
- Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian and Primary Peritoneal Malignancies: Single Institutional ExperienceLabow D, Zakashansky K, Sarpel U, Fishman D, Rahaman J, Kolev V, Fields J, Farag S, Tabrizian P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian and Primary Peritoneal Malignancies: Single Institutional Experience. International Journal Of Gynecological And Obstetrical Research 2016, 3: 53-59. DOI: 10.14205/2309-4400.2015.03.02.2.
- Clinical Outcomes of Type II Endometrial Cancer in Open Versus Minimally Invasive Staging SurgeryFarag S, Andikyan V, Fields J, Kanis M, Rahaman J, Kolev V, Hayes M. Clinical Outcomes of Type II Endometrial Cancer in Open Versus Minimally Invasive Staging Surgery. Journal Of Minimally Invasive Gynecology 2015, 22: s229. PMID: 27679118, DOI: 10.1016/j.jmig.2015.08.806.
- Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the CervixHachem L, Pereira E, Momeni M, Andikyan V, Nguyen L, Stevens R, Raff J, Eisen R, Gretz H. Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. Journal Of Minimally Invasive Gynecology 2015, 22: s143. PMID: 27678792, DOI: 10.1016/j.jmig.2015.08.495.
- Laparoscopic Removal of Streak Gonads in Turner SyndromeMandelberger A, Mathews S, Andikyan V, Chuang L. Laparoscopic Removal of Streak Gonads in Turner Syndrome. Journal Of Minimally Invasive Gynecology 2015, 22: s15. PMID: 27678838, DOI: 10.1016/j.jmig.2015.08.048.
- MicroRNA activity profile in the ovarian cancer cell line OVCAR3 identifies a proapoptotic effect of miR-23aAndikyan V, Baccarini A, Mullokandov G, Agudo J, Sachidanandam R, Fishman D, Brown B. MicroRNA activity profile in the ovarian cancer cell line OVCAR3 identifies a proapoptotic effect of miR-23a. Advances In Genomics And Genetics 2015, Volume 5: 355-364. DOI: 10.2147/agg.s86586.
- Abstract 5589: Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyomaBrohl A, Li L, Andikyan V, Cioffi A, Dudley J, Kasarskis A, Maki R. Abstract 5589: Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. 2015, 5589-5589. DOI: 10.1158/1538-7445.am2015-5589.
- Role of laparoscopy in determining optimal cytoreduction in patients with ovarian, fallopian tube and primary peritoneal cancerAndikyan V, Kim A, Sierra T, Gretz H, Zakashansky K, Segna R, Beddoe A, Dottino P, Mandeli J, Chuang L. Role of laparoscopy in determining optimal cytoreduction in patients with ovarian, fallopian tube and primary peritoneal cancer. Gynecologic Oncology 2015, 137: 103. DOI: 10.1016/j.ygyno.2015.01.255.
- Depression scores before and after in-office evaluations in patients undergoing ovarian cancer screeningFarag S, Chu M, Nguyen L, Andikyan V, Pereira E, Moshier E, Wilson S, Vaidya S, Fishman D. Depression scores before and after in-office evaluations in patients undergoing ovarian cancer screening. Gynecologic Oncology 2015, 137: 193. DOI: 10.1016/j.ygyno.2015.01.485.
- Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experienceAndikyan V, Tabrizian P, Farag S, Fields J, Kolev V, Rahaman J, Fishman D, Sarpel U, Zakashansky K, Labow D. Hyperthermic intraperitoneal chemotherapy for treatment of ovarian and primary peritoneal cancer: Single institutional experience. Gynecologic Oncology 2015, 137: 173-174. DOI: 10.1016/j.ygyno.2015.01.434.
- Surgical, pathologic and survival outcomes of patients undergoing open, laparoscopic or robotic radical hysterectomy for invasive cervical cancerAndikyan V, Carroll R, Fields J, Gretz H, Chuang L, Dottino P, Zakashansky K. Surgical, pathologic and survival outcomes of patients undergoing open, laparoscopic or robotic radical hysterectomy for invasive cervical cancer. Gynecologic Oncology 2015, 137: 144-145. DOI: 10.1016/j.ygyno.2015.01.361.
- Anxiety in patients undergoing ovarian cancer screening before and after in-office evaluationFarag S, Chu M, Nguyen L, Andikyan V, Pereira E, Moshier E, Wilson S, Vaidya S, Fishman D. Anxiety in patients undergoing ovarian cancer screening before and after in-office evaluation. Gynecologic Oncology 2015, 137: 124-125. DOI: 10.1016/j.ygyno.2015.01.311.
- Does use of uterine manipulator alter the rate of lymphovascular space invasion in patients with invasive cervical cancer undergoing radical hysterectomy?Andikyan V, Carroll R, Fields J, Dottino P, Zakashansky K. Does use of uterine manipulator alter the rate of lymphovascular space invasion in patients with invasive cervical cancer undergoing radical hysterectomy? Gynecologic Oncology 2015, 137: 145. DOI: 10.1016/j.ygyno.2015.01.362.
- Urinary diversion: ConduitKhoury-Collado F, Andikyan V, Bochner B. Urinary diversion: Conduit. 2013, 257-263. DOI: 10.1201/b15258-30.
- Extended pelvic resections and laterally extended endopelvic resectionsAndikyan V, Khoury-Collado F, Boland P, Chi D. Extended pelvic resections and laterally extended endopelvic resections. 2013, 241-248. DOI: 10.1201/b15258-28.
- Pelvic exenterationAndikyan V, Khoury-Collado F, Bochner B, Chi D. Pelvic exenteration. 2013, 225-240. DOI: 10.1201/b15258-27.
- Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: Is less enough?Andikyan V, Khoury-Collado F, Denesopolis J, Sandadi S, Park K, Brown C, Sonoda Y, Chi D, Barakat R, Abu-Rustum N. Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: Is less enough? Gynecologic Oncology 2013, 130: e50. DOI: 10.1016/j.ygyno.2013.04.179.
- Revolving door of obstruction – An analysis of gynecologic oncology readmissionPhelps S, Andikyan V, Denesopolis J, Rodriguez E, Tew W, Martin S, Hoskins W, Barakat R, Chi D, Makker V. Revolving door of obstruction – An analysis of gynecologic oncology readmission. Gynecologic Oncology 2013, 130: e59. DOI: 10.1016/j.ygyno.2013.04.202.
- Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancerSandadi S, Long K, Andikyan V, Vernon J, Sonoda Y, Barakat R, Chi D. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecologic Oncology 2013, 130: e110. DOI: 10.1016/j.ygyno.2013.04.320.
- Urologic outcomes following modified Indiana pouch during pelvic exenteration for gynecologic malignanciesAndikyan V, Khoury-Collado F, Hobeika E, Lee S, Abu-Rustum N, Sonoda Y, Sandhu J, Barakat R, Bochner B, Chi D. Urologic outcomes following modified Indiana pouch during pelvic exenteration for gynecologic malignancies. Gynecologic Oncology 2013, 130: e109-e110. DOI: 10.1016/j.ygyno.2013.04.318.
- OC-46 HIGH DOSE RATE (HDR) INTRAOPERATIVE BRACHYTHERAPY IN THE MANAGEMENT OF RECURRENT GYNECOLOGIC MALIGNANCIESScala L, Chi D, Bochner B, Andikyan V, Gerst S, Sandhu J, Boland P, Sonoda Y, Alektiar K. OC-46 HIGH DOSE RATE (HDR) INTRAOPERATIVE BRACHYTHERAPY IN THE MANAGEMENT OF RECURRENT GYNECOLOGIC MALIGNANCIES. Radiotherapy And Oncology 2012, 103: s19-s20. DOI: 10.1016/s0167-8140(12)72013-3.
- Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcomeAndikyan V, Khoury-Collado F, Gerst S, Talukdar S, Bochner B, Sandhu J, Abu-Rustum N, Sonoda Y, Barakat R, Chi D. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome. Gynecologic Oncology 2012, 126: 346-350. PMID: 22555107, DOI: 10.1016/j.ygyno.2012.04.034.
- Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out-of-the-box surgeryAndikyan V, Collado F, Sonoda Y, Gerst S, Alektiar K, Sandhu J, Bochner B, Barakat R, Boland P, Chi D. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out-of-the-box surgery. Gynecologic Oncology 2012, 125: s12. DOI: 10.1016/j.ygyno.2011.12.027.
- A prospective study of the feasibility and acceptability of a web-based, electronic patient-reported outcomes system in assessing patient recovery after major gynecologic cancer surgeryAndikyan V, Rezk Y, Einstein M, Zivanovic O, Leitao M, Sonoda Y, Abu-Rustum N, Barakat R, Basch E, Chi D. A prospective study of the feasibility and acceptability of a web-based, electronic patient-reported outcomes system in assessing patient recovery after major gynecologic cancer surgery. Gynecologic Oncology 2012, 125: s118. DOI: 10.1016/j.ygyno.2011.12.285.
- Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgeryAndikyan V, Khoury-Collado F, Sonoda Y, Gerst S, Alektiar K, Sandhu J, Bochner B, Barakat R, Boland P, Chi D. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery. Gynecologic Oncology 2012, 125: 404-408. PMID: 22285844, DOI: 10.1016/j.ygyno.2012.01.031.
- Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer NeoplasieAndikyan V, Kronschnabl M, Hillemanns M, Wang X, Stepp H, Hillemanns P. Fluoreszenzdiagnostik mit 5-ALA-Thermogel bei zervikaler intraepithelialer Neoplasie. Gynäkologische Rundschau 2003, 44: 31-37. PMID: 14673226, DOI: 10.1159/000074315.
- Morphofunctional changes in the placenta after ozone therapyAndikyan V, Voloshchuk I, Kovganko P, Clemente J. Morphofunctional changes in the placenta after ozone therapy. Bulletin Of Experimental Biology And Medicine 2000, 130: 715-718. PMID: 11140595, DOI: 10.1007/bf02682114.